Loading...
XSTO
BIOG B
Market cap1.22bUSD
Jul 09, Last price  
119.30SEK
1D
0.93%
1Q
-0.58%
Jan 2017
98.83%
Name

Biogaia AB

Chart & Performance

D1W1MN
XSTO:BIOG B chart
P/E
35.31
P/S
7.64
EPS
3.38
Div Yield, %
5.78%
Shrs. gr., 5y
0.04%
Rev. gr., 5y
15.54%
Revenues
1.54b
+8.11%
86,792,000106,580,000145,190,000203,461,000236,033,000314,992,000645,252,000315,875,000481,802,000483,241,000534,696,000615,003,000741,870,000768,348,000747,077,000785,111,0001,103,958,0001,296,506,0001,422,718,0001,538,168,000
Net income
333m
-5.30%
2,720,00019,659,00036,121,00036,045,00047,168,00076,369,000326,970,00061,722,000147,406,000121,408,000227,568,000180,564,000214,890,000187,347,000179,730,000196,273,000373,773,000365,352,000351,388,000332,764,000
CFO
307m
-17.86%
-831,0005,088,00019,204,00053,290,00068,965,00072,792,000335,557,00078,441,000124,383,000117,501,000147,929,000222,615,000183,120,000147,855,000221,256,000221,875,000318,943,000425,965,000373,218,000306,566,000
Dividend
May 08, 20256.9 SEK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BioGaia AB (publ), a Swedish enterprise founded in 1990 and headquartered in Stockholm, is dedicated to the worldwide development, marketing, and distribution of probiotic products renowned for their scientifically proven health advantages. The company operates through three primary divisions. Its Pediatrics segment offers various items such as drops, oral rehydration solutions, and gut health tablets, in addition to supplying cultures for integration into infant formula. The Adult Health segment provides gut health tablets and oral health lozenges, alongside furnishing cultures to licensees for use in dairy products. A third segment, "Other," specializes in packaging solutions. BioGaia's extensive product portfolio targets a range of health issues, including infantile colic and digestive health in children, antibiotic-associated and acute diarrhea, gingivitis, periodontal disease, general well-being, Helicobacter pylori bacterial infections (linked to gastric ulcers), and concerns related to low bone density. All of its offerings are sold exclusively under the BioGaia brand.
IPO date
Jan 01, 1998
Employees
215
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT